| Scrip Code | 500257 |
|---|---|
| NSE Symbol | LUPIN |
| MSEI Symbol | NOTLISTED |
| ISIN | INE326A01037 |
| Name of company | Lupin Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 12-02-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 28-01-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 12-02-2026 18:30:00 |
| End date and time of board meeting | 12-02-2026 20:40:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 7,16,752.00 | 20,48,337.00 | |
| Other income | 11,470.00 | 28,374.00 | |
| Total income | 7,28,222.00 | 20,76,711.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 1,12,482.00 | 3,39,060.00 |
| (b) | Purchases of stock-in-trade | 71,973.00 | 2,15,860.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 3,358.00 | (7,437.00) |
| (d) | Employee benefit expense | 1,14,328.00 | 3,33,183.00 |
| (e) | Finance costs | 11,498.00 | 31,433.00 |
| (f) | Depreciation, depletion and amortisation expense | 31,296.00 | 92,871.00 |
| (f) | Other Expenses | ||
| 1 | Other expenses | 1,93,662.00 | 5,68,823.00 |
| 2 | Net (gain) / loss on foreign currency transactions | (5,236.00) | (34,196.00) |
| Total other expenses | 1,88,426.00 | 5,34,627.00 | |
| Total expenses | 5,33,361.00 | 15,39,597.00 | |
| 3 | Total profit before exceptional items and tax | 1,94,861.00 | 5,37,114.00 |
| 4 | Exceptional items | (42,657.00) | (42,657.00) |
| 5 | Total profit before tax | 1,52,204.00 | 4,94,457.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 20,455.00 | 1,01,943.00 |
| 8 | Deferred tax | 13,698.00 | 3,832.00 |
| 9 | Total tax expenses | 34,153.00 | 1,05,775.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 1,18,051.00 | 3,88,682.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 1,18,051.00 | 3,88,682.00 |
| 17 | Other comprehensive income net of taxes | 12,010.00 | 37,614.00 |
| 18 | Total Comprehensive Income for the period | 1,30,061.00 | 4,26,296.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 1,17,555.00 | 3,87,252.00 | |
| Total profit or loss, attributable to non-controlling interests | 496.00 | 1,430.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 1,29,570.00 | 4,24,651.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 491.00 | 1,645.00 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 9,137.00 | 9,137.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 25.74 | 84.79 | |
| Diluted earnings (loss) per share from continuing operations | 25.67 | 84.56 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 25.74 | 84.79 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 25.67 | 84.56 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 12, 2026. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. U.S.A., Lupin Australia Pty Limited Australia, Nanomi B.V. Netherlands, Pharma Dynamics Proprietary Limited South Africa, Hormosan Pharma GmbH Germany, Multicare Pharmaceuticals Philippines Inc. Philippines, Lupin Atlantis Holdings SA Switzerland, Lupin Healthcare UK Limited U.K., Lupin Pharma Canada Limited Canada, Generic Health Pty Limited Australia, Lupin Mexico S.A. de C.V. Mexico, Lupin Philippines Inc. Philippines, Lupin Diagnostics Limited India, Generic Health SDN. BHD. Malaysia, Lupin Inc. U.S.A., Laboratorios Grin S.A. de C.V. Mexico, Medquimica Industria Farmaceutica LTDA Brazil, Novel Laboratories, Inc. U.S.A., Lupin Research Inc. U.S.A., Lupin Management Inc. U.S.A, Lupin Europe GmbH Germany, Lupin Biologics Limited India, Lupin Oncology Inc. U.S.A, Lupin Digital Health Limited India, Avenue Coral Springs LLC U.S.A., Southern Cross Pharma Pty Ltd Australia, Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India, Lupin Manufacturing Solutions Limited India, Medisol S.A.S. France, Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05, 2024, Lupin NZ Ltd. New Zealand w.e.f. August 08, 2024, Lupinlife Consumer Healthcare Limited India w.e.f. March 08, 2025, Renascience Pharma Limited U.K. w.e.f. April 02, 2025 and a joint venture, YL Biologics Limited Japan. 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. 4. During the quarter ended December 31, 2025, 40,938 yearto date 233,761 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up share capital by Rs. 0.1 million year to date Rs. 0.5 million and securities premium account by Rs. 40.9 million year to date Rs. 256.5 million. 5. Exceptional items a. Lupin Limited and its US subsidiary were named in class action and individual cases related to Antitrust Litigations for certain products. The Company intends to settle the matter with certain parties without admitting any liability for any wrongdoing and accordingly has created a provision of Rs. 4,493.9 million USD 50.0 million during the quarter and nine months ended December 31, 2025. b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. The Company has agreed to pay USD 90.0 million, which includes USD 75.0 million towards Prepaid Option. During the quarter and nine months ended December 31, 2025 the Group has provided Rs. 1,348.1 million USD 15.0 million for one time payment towards this settlement. c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the New Labour Codes. The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 512.2 million during the quarter and nine months ended December 31, 2025. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. d. During the quarter and nine months ended December 31, 2025, the Group entered into a settlement agreement with an income of Rs. 873.7 million USD 10.0 million. e. During the quarter, the Group has received an arbitration award, consequently accounted an income of Rs. 603.2 million USD 6.9 million and a reversal of expense provision of Rs. 611.6 million USD 7.0 million. 6. During the nine months ended December 31, 2025, the Company through its wholly owned subsidiary Nanomi B.V., Netherlands Nanomi has entered into a definitive agreement to acquire 100 share capital of VISUfarma B.V., Netherlands, for a consideration of EUR 190.0 million subject to closing adjustments. Pending regulatory approval, no impact has been given in the results. The acquisition related costs are accounted in Other expenses. 7. During the nine months ended December 31, 2025, the Company through its wholly owned stepdown subsidiary, Lupin Healthcare UK Limited, U.K., acquired 100 equity share capital of Renascience Pharma Limited, U.K., for a consideration of Rs. 1,361.6 million GBP 12.3 million. Fair value of intangibles acquired Rs. 1,239.4 million, deferred tax liability Rs. 309.8 million, Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. 8. During the nine months ended December 31, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 9. During the year ended March 31, 2025, the Group has recognised an impairment charge of Rs. 1,209.0 million related to certain property, plant and equipment, capital workinprogress, intangible assets, intangible assets under development and goodwill. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Pharmaceuticals | 7,13,089.00 | 20,37,762.00 | ||||
| 2 | Others | 3,696.00 | 10,692.00 | ||||
| 3 | Less: Inter segment | 0.00 | 0.00 | ||||
| Total Segment Revenue | 7,16,785.00 | 20,48,454.00 | |||||
| Less: Inter segment revenue | 33.00 | 117.00 | |||||
| Revenue from operations | 7,16,752.00 | 20,48,337.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Pharmaceuticals | 1,56,735.00 | 5,07,319.00 | ||||
| 2 | Others | (4,531.00) | (12,862.00) | ||||
| 3 | Less: Inter segment | 0.00 | 0.00 | ||||
| Total Profit before tax | 1,52,204.00 | 4,94,457.00 | |||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | 1,52,204.00 | 4,94,457.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Pharmaceuticals | 34,97,486.00 | 34,97,486.00 | ||||
| 2 | Others | 25,309.00 | 25,309.00 | ||||
| 3 | Less: Inter segment | (379.00) | (379.00) | ||||
| Total Segment Asset | 35,22,416.00 | 35,22,416.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 35,22,416.00 | 35,22,416.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Pharmaceuticals | 14,09,466.00 | 14,09,466.00 | ||||
| 2 | Others | 9,984.00 | 9,984.00 | ||||
| 3 | Less: Inter segment | (365.00) | (365.00) | ||||
| Total Segment Liabilities | 14,19,085.00 | 14,19,085.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 14,19,085.00 | 14,19,085.00 | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified subsequently to profit or loss | (593.00) | (691.00) |
| Total Amount of items that will not be reclassified to profit and loss | (593.00) | (691.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (270.00) | (204.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified subsequently to profit or loss | 12,288.00 | 36,780.00 |
| Total Amount of items that will be reclassified to profit and loss | 12,288.00 | 36,780.00 | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | (45.00) | (1,321.00) |
| 5 | Total Other comprehensive income | 12,010.00 | 37,614.00 |